SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC

Key Points

The aim is to evaluate the efficacy of olomorasib and pembrolizumab with or without chemotherapy in treating KRAS G12C non-small cell lung cancer (NSCLC).
Trial registration: NCT06119581 and EudraCT: 2023-503412-33-00.
Participants include those diagnosed with KRAS G12C NSCLC.
Intervention involves olomorasib and pembrolizumab, with comparison to chemotherapy.
Efficacy outcomes for olomorasib and pembrolizumab assessed in context of NSCLC.
Expected insights into combination therapies for KRAS G12C mutations.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Innovative trial investigates outcomes of olomorasib and pembrolizumab in NSCLC, suggesting new treatment strategies.

www.clinicaltrials.gov identifier is NCT06119581. EudraCT: 2023-503412-33-00.

No takes yet. Share an insight, caveat, or question.

Peters et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share